Myelodysplastic syndrome - lenalidomide

The Pharmaceutical Benefits Scheme (PBS) subsidises lenalidomide for patients with myelodysplastic syndrome.

Patient eligibility

The PBS subsidises treatment with lenalidomide under the National Health Act 1953, section 100 for patients with myelodysplastic syndrome.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing lenalidomide.

Section 100 arrangements

This item is only PBS subsidised for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

This item isn’t PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Applying for initial or first continuing treatment

Patients receiving lenalidomide under this PBS listing must be registered in the i-access risk management program.

Apply for initial or first continuing authority approval to prescribe PBS subsidised lenalidomide to treat myelodysplastic syndrome in writing and either:

All applications must include the completed:

Applying for subsequent continuing treatment

Subsequent continuing authority applications to prescribe PBS subsidised lenalidomide to treat myelodysplastic syndrome can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 2 June 2020